Modern treatment strategies in pediatric oncology and hematology
- PMID: 37314524
- PMCID: PMC10267092
- DOI: 10.1007/s12672-023-00658-7
Modern treatment strategies in pediatric oncology and hematology
Abstract
Every year, approximately 400 00 children worldwide are diagnosed with cancer. Although treatment results in most types of childhood neoplasms are excellent with survival more than 80%, there are some with poor prognosis. Also recurrent and resistant to treatment childhood cancer remain a therapeutic challenge. Besides chemotherapy, which has been the basis of cancer therapy for years, molecular methods and precisely targeted therapies have recently found their usage. As a result of that, survival has improved and has positively impacted the rate of toxicities associated with chemotherapy (Butler et al. in CA Cancer J Clin 71:315-332, 2021). These achievements have contributed to better quality of patients' lives. Current methods of treatment and ongoing trials give hope for patients with relapses and resistance to conventional chemotherapy. This review focuses on the most recent progress in pediatric oncology treatments and discusses specific therapy methods for particular cancers types of cancer. Targeted therapies and molecular approaches have become more beneficial but research need to be continued in this field. Despite significant breakthroughs in pediatric oncology in the last few years, there is still a need to find new and more specific methods of treatment to increase the survival of children with cancer.
Keywords: Immunotherapy; Neoplasm; Pediatric oncology; Targeted therapy; Treatment.
© 2023. The Author(s).
Conflict of interest statement
Not applicable.
Figures
Similar articles
-
The Challenge of Developing New Therapies for Childhood Cancers.Oncologist. 1997;2(1):I-II. Oncologist. 1997. PMID: 10388032
-
Treatments for astrocytic tumors in children: current and emerging strategies.Paediatr Drugs. 2006;8(3):167-78. doi: 10.2165/00148581-200608030-00003. Paediatr Drugs. 2006. PMID: 16774296 Review.
-
Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.Med Oncol. 2017 Sep 1;34(10):170. doi: 10.1007/s12032-017-1029-8. Med Oncol. 2017. PMID: 28864844 Review.
-
The therapy of infantile malignant brain tumors: current status?J Neurooncol. 2005 Dec;75(3):279-85. doi: 10.1007/s11060-005-6752-x. J Neurooncol. 2005. PMID: 16195802 Review.
-
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Eur J Pharm Biopharm. 2015. PMID: 25813885 Review.
Cited by
-
Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in a Cohort of Hungarian Pediatric Patients with Hematological and Oncological Disorders: A Pilot Study.Int J Mol Sci. 2024 Aug 14;25(16):8831. doi: 10.3390/ijms25168831. Int J Mol Sci. 2024. PMID: 39201517 Free PMC article.
-
Considerations on Design and Analysis of External Control in Pediatric Oncology.Med Res Arch. 2024 Jan;12(1):10.18103/mra.v12i1.5088. doi: 10.18103/mra.v12i1.5088. Epub 2024 Mar 4. Med Res Arch. 2024. PMID: 39026931 Free PMC article.
-
Feasibility, efficacy, and safety of animal-assisted activities with visiting dogs in inpatient pediatric oncology.World J Pediatr. 2024 Sep;20(9):915-924. doi: 10.1007/s12519-024-00829-8. Epub 2024 Aug 7. World J Pediatr. 2024. PMID: 39112809 Free PMC article.
-
Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers.Nat Med. 2024 Apr;30(4):990-1000. doi: 10.1038/s41591-024-02848-4. Epub 2024 Apr 11. Nat Med. 2024. PMID: 38605166 Free PMC article.
-
Medication safety with oral antitumour therapeutics in paediatrics (youngAMBORA): A mixed-methods approach towards a tailored care program.PLoS One. 2024 Dec 5;19(12):e0315077. doi: 10.1371/journal.pone.0315077. eCollection 2024. PLoS One. 2024. PMID: 39637156 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials